Imugene Ltd
ASX:IMU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Imugene Ltd
Cash & Cash Equivalents
Imugene Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Imugene Ltd
ASX:IMU
|
Cash & Cash Equivalents
AU$14.1m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
14%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash & Cash Equivalents
$129.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
1%
|
|
|
CSL Ltd
ASX:CSL
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash & Cash Equivalents
AU$20.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash & Cash Equivalents
AU$141.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash & Cash Equivalents
AU$120.7m
|
CAGR 3-Years
92%
|
CAGR 5-Years
38%
|
CAGR 10-Years
29%
|
|
Imugene Ltd
Glance View
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
See Also
What is Imugene Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
14.1m
AUD
Based on the financial report for Dec 31, 2025, Imugene Ltd's Cash & Cash Equivalents amounts to 14.1m AUD.
What is Imugene Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
14%
Over the last year, the Cash & Cash Equivalents growth was -58%. The average annual Cash & Cash Equivalents growth rates for Imugene Ltd have been -56% over the past three years , -16% over the past five years , and 14% over the past ten years .
